Provectus Pharmaceuticals (otc bb "pvct") announced today that the Company has an active IND (Investigational New Drug) application for XantrylTM drug therapy with the FDA for Psoriasis.
Provectus Pharmaceuticals Inc., OTC BB “PVCT” is a pioneering pharmaceutical company actively engaged in the design, development and marketing of a diverse portfolio of leading patented pharmaceutical technologies for treatment of liver, breast and prostate cancer. In addition, Provectus has developed and patented treatments for skin diseases, psoriasis and a variety of other skin condition products.
(PRWEB) November 16, 2003
Provectus Pharmaceuticals (otc bb "pvct") announced today that the Company has an active IND (Investigational New Drug) application for XantrylTM drug therapy with the FDA for Psoriasis.
Provectus Pharmaceuticals has completed successful HUMAN pre-clinical trials in Europe and a number of Phase I trials in the US. Provectus Psoriasis drug, XantrylTM, is now ready for Phase II/III HUMAN studies. Psoriasis is a chronic disease and represents a market opportunity of over $1 billion
The company is advancing the development of XantrylTM which is activated by green light for the treatment of psoriasis. One of the standard treatments of psoriasis is photodynamic therapy using drugs activated by ultraviolet light that cross-link cellular genetic material. A hazard associated with this therapy is the potential to develop skin cancer. Several new drugs have been developed that act by suppressing the immune system. These drugs are expensive and require repeated injections. The potential for severe suppression of the immune system may limit the use of some of the new drugs to just a few treatments.
In contrast, XantrylTM specifically targets only diseased tissue and the effects of light activation are confined only to areas of the skin affected by psoriasis. The agent is so sensitive to light that only ambient room or sun light maybe required for treatment. This would remove the requirement for repeated visits to a physician. A green laser in the physicianÂ’s office or a simple tanning bed can also activate the drug. Since the effects of the treatment are confined only to areas affected by psoriasis the chance of side effects are slight.
Provectus Pharmaceuticals, Inc. develops pharmaceutical products in three sectors of the health-care industry: 1) prescription medications, 2) medical devices, and 3) OTC pharmaceuticals and cosmetics. Prescription drug products and devices treat diseases of the skin and many types of cancer. OTC products address complementary markets, primarily those involving skin care and comfort.
The company's corporate offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, Tenn. 37931; 865/769-4012. For more information, contact the company at info@provectuscorp. com or visit the corporate Web site: www. provectuscorp. com.
Forward-Looking Statements
This release and others statements issued or made from time to time by the company or its representatives contain statements that may constitute forward-looking statements. Those statements include statements regarding the intent, belief or current expectations of the company and members of its management teams as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
###
Corporate Contact: Provectus Pharmaceuticals, Craig Dees, CEO (865) 769-4011
Media Contacts:
